Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453897 | 0.96 | CA1 (0.56) | CA1CA2CA7CA9TSHR | |
| SCHEMBL14453900 | 0.92 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL6068726 | 0.89 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL6068730 | 0.89 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL10052085 | 0.89 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL24305309 | 0.87 | CA1 (0.49) | CA1CA2CA7CA9TSHR | |
| SCHEMBL21848157 | 0.87 | TSHR (0.67) | CA1CA2CA7CA9TSHR | |
| SCHEMBL31647529 | 0.86 | CA1 (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL18652013 | 0.86 | CA1 (0.47) | CA1CA2CA7CA9TSHR | |
| SCHEMBL4300148 | 0.84 | CA1 (0.46) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731619-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF BISPECIFIC RBP4/TTR LIGAND AND C20-D3-RETINOL | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| WO-2024263782-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF BISPECIFIC RBP4/TTR LIGAND AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION AND TTR AMYLOIDOSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | claimed |
| CN-108314665-B | A kind of preparation method of 3- oxetanes formic acid | 上海馨远医药科技有限公司 | 2019-04-23 | — | — | CN | claimed |
| CN-108314665-A | A kind of preparation method of 3- oxetanes formic acid | 上海馨远医药科技有限公司 | 2018-07-24 | — | — | CN | claimed |
| EP-4731619-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF BISPECIFIC RBP4/TTR LIGAND AND C20-D3-RETINOL | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731618-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE TTR LIGAND AND C20-D3-RETINOL | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4709710-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4702044-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2026-03-04 | — | — | EP | disclosed |
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260021193-A1 | IMMUNOCONJUGATES AND METHODS | IMMUNOME INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250281519-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2025-09-11 | — | — | US | disclosed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
| US-5854228-A | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1998-12-29 | — | — | US | disclosed |
| US-5808108-A | DENTAL COMPOSITES | CURATORS OF THE UNIVERISITY OF MISSOURI | 1998-09-15 | — | — | US | disclosed |
| US-5650510-A | VIRICIDES OR ANTITUMOR AGENTS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-07-22 | — | — | US | disclosed |
| EP-0269947-B2 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | ACAD OF SCIENCE CZECH REPUBLIC (CS) | 1996-10-16 | — | — | EP | disclosed |
| EP-0269947-A1 | Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | CA1 4323/4885CA2 2132/4885CA7 4579/4885 |
| US-20250281519-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | NTPCR, TYMP, MTAP | CA1 4466/4885CA2 4579/4885CA7 3757/4885 |
| US-20260021193-A1 | IMMUNOCONJUGATES AND METHODS | FCGR3B, FCGR2A, FCGRT | CA1 760/4885CA2 1946/4885CA7 350/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | CA1 4490/4885CA2 3398/4885CA7 4617/4885 |
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | CA1 4612/4885CA2 3798/4885CA7 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.